Collaborative Research program in Biomedical Innovation Law

The overall aim and ambition of CeBIL is to contribute to the translation of groundbreaking biomedical research into safe, effective, affordable and accessible therapies by analyzing the most significant legal challenges to pharmaceutical innovation and public health from a holistic cross-disciplinary perspective.


CeBIL addresses fundamental legal challenges in the pharma and life sciences taking into account the eco-system of bio-pharmaceutical innovation and health-care. The Research Program’s unique focus on biomedical innovation law that cuts across various legal disciplines and brings in interdisciplinary, industry and policy perspectives provides an important contribution to the future of the bio-pharmaceutical innovation system. During the first 5 years, CeBIL focuses on Innovation Inefficiencies on the Life Science Frontiers through 5 concrete interrelated studies complemented by a 6th synergy study.

Table of study six: synergy and policy solutions






















Internal Researchers

Name Title Image
Belay, Dagim Assistant Professor - Tenure Track Billede af Belay, Dagim
Corrales Compagnucci, Marcelo Associate Professor Billede af Corrales Compagnucci, Marcelo
Floryan, Leonard Research Assistant Billede af Floryan, Leonard
Minssen, Timo Head of Centre, Professor Billede af Minssen, Timo

External Researchers


Novo Nordisk Foundation

CeBIL is supported by a grant of DKK 35 million from the Novo Nordisk Foundation

Project: Collaborative Research Program in Biomedical Innovation Law


Period: 2018-2023


Timo MinssenPI Director of centre, professor
Timo Minssen

South Campus,
Building: 6B.3.09A
DK-2300 Copenhagen S
Phone: +46 70 86 07 517

Core partners

University of Copenhagen
University of Cambridge
Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, Harvard Law School
PORTAL - Program on Regulation, Therapeutics and Law, Harvard Medical School and Brigham & Women’s Hospital
University of Michigan Law School